BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
38 hedge funds and large institutions have $2.52M invested in BRAINSTORM CELL THERAPUTC in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 14 closing their positions.
45% more call options, than puts
Call options by funds: $42K | Put options by funds: $29K
0.25% less ownership
Funds ownership: 1.16% → 0.92% (-0.25%)
21% less funds holding
Funds holding: 48 → 38 (-10)
38% less capital invested
Capital invested by funds: $4.09M → $2.52M (-$1.57M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.5K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$7.54K |
| 4 |
Morgan Stanley
New York
|
+$3.93K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$3.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$321K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$30.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$25.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.9K |
| 5 |
VF
Virtu Financial
New York
|
-$17K |
BCLI Hedge Fund Activity: Q3 2024 in Review
38 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2024, worth a combined $2.52M — down 38% from $4.09M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BCLI and 5 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $62.5K. The largest seller was Armistice Capital, cutting an estimated $321K.
- 38 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $2.52M of BRAINSTORM CELL THERAPUTC stock for Q3 2024, down 38% quarter-over-quarter.
- 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2024 and 14 closed out, a net change of -9 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2024 was Geode Capital Management, an estimated $62.5K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2024 was Armistice Capital, an estimated $321K sold.
Based on aggregated 13F filings for Q3 2024.